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Background: We determined factors associated with self-reported decline in activities of daily 
living (ADLs) and symptoms of cognitive impairment in HIV positive (HIV+) adults in five 
European clinics. 
Methods: HIV+ adults underwent computerized and pen-and-paper neuropsychological tests 
and questionnaires of cognitive symptoms and ADLs. We considered cognitive function in five 
domains, psychosocial factors and clinical parameters as potentially associated with symptoms. 
Separate regression analyses were used to determine factors associated with decline in ADL 
(defined as self-reported decline affecting ≥2 ADLs and attributed to cognitive difficulties) and 
self-reported frequency of symptoms of cognitive impairment. We also estimated the diagnostic 
accuracy of both questionnaires as tests for cognitive impairment. 
Results: 448 patients completed the assessments (mean age 45.8 years, 84% male, 87% white, 
median CD4 count 550 cells/mm3, median time since HIV diagnosis 9.9 years, 81% virologically 
suppressed [HIV-1 plasma RNA <50 copies/mL]). Ninety-six (21.4%) reported decline in ADLs 
and attributed this to cognitive difficulties. Self-reported decline in ADLs and increased 
symptoms of cognitive impairment were both associated with worse performance on some 
cognitive tests. There were also strong associations with financial difficulties, depressive and 
anxiety symptoms, unemployment, and longer time since HIV diagnosis. Both questionnaires 
performed poorly as diagnostic tests for cognitive impairment. 
Conclusion: Patients’ own assessments of everyday function and symptoms were associated 
with objectively-measured cognitive function. However, there were strong associations with 
other psychosocial issues including mood and anxiety disorders and socioeconomic hardship. 
This should be considered when assessing HIV-associated cognitive impairment in clinical care 
or research studies. 
 
Key words: HIV; HIV dementia; neuropsychological assessment; MCI (mild cognitive 
impairment); activities of daily living. 
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INTRODUCTION 
 
Several studies have reported high prevalence of cognitive impairment in HIV+ patients, with 
the highest estimates exceeding 50%.1, 2 However, a large proportion of individuals scoring 
below specified thresholds on cognitive testing and meeting the criteria for HIV-associated 
neurocognitive disorder (HAND) have no interference with everyday functioning, and are 
categorised as having Asymptomatic Neurocognitive Impairment (ANI) by the Frascati criteria.3 
Others have used participant self-report methods such as the modified Lawton & Brody 
Instrumental Activities of Daily Living Scale (IADLS) to discriminate Mild Neurocognitive 
Disorder (MND) from ANI.2, 4-6 Deterioriation, if defined as a change from ANI to MND, is based 
solely on the assessment of difficulties with activities of daily living (ADL), therefore discerning 
this change is highly important. Functional decline and cognitive symptoms may also be the 
main driver of patients coming to clinicians’ attention in clinical settings.  
 
Some studies have suggested limited validity of patient self-report with commonly-used 
questionnaires when used to predict objectively-measured cognitive function.7-10 But even if 
symptoms are only weakly correlated with cognitive impairment, they are in some sense highly 
important to the patient. There are likely to be psychological and other factors underlying 
reported symptoms, and understanding these factors may steer the clinician away from 
investigations such as brain imaging and lumbar puncture and towards the patients’ more 
pertinent needs. In this analysis, we aimed to measure the strength of association between self-
reported decline in ADL, self-reported symptoms of cognitive impairment, and objectively-
measured cognitive function. We then sought to determine which other factors were associated 
with these symptoms of cognitive difficulties.  
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Methods 
 
Participants 
CIPHER is a European study of cognitive function in HIV+ adult outpatients (two clinics in 
London, UK; one clinic in each of: Copenhagen, Denmark; Minsk, Belarus; Rome, Italy). We 
recently reported, along with detailed psychosocial and clinical cofactors, a 35% prevalence of 
cognitive impairment, of whom more than half met Frascati criteria for ANI and a quarter had 
confounding conditions, with the remaining 6% having MND or HAD.11 Participants were 
recruited opportunistically from May 2011 to January 2013 regardless of symptoms, treatment 
and comorbidities. All questionnaires were self-completed in a written format by the participant 
in the local language, and participants had to be sufficiently cognitively intact to complete study 
procedures. 
 
Ethical approval 
The study was approved by the UK National Research Ethics Service – London Hampstead 
Committee (11/LO/0077), De Videnskabsetiske Komiteér for Region Hovedstaden (H-4-2011-
105), the Ethics Committee of the Minsk Municipal Infectious Diseases Hospital (04/2011), and 
the Comitato Etico of Istituto Nazionale Malattie Infettive (66/2011). All study participants gave 
written informed consent prior to commencing the study. 
 
Assessment of symptoms and self-reported function 
Declining function in ADLs was measured using the Modified Lawton & Brody IADLS, which 
required participants to indicate their current and, retrospectively, their “best ever” level of 
function on sixteen activities, according to a 3- or 4-point scale (see Supplemental Digital 
Content 1). Where their current level was worse than their best ever level, participants 
recorded the perceived cause as “primarily cognitive problems”, “primarily physical problems”, 
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or “equally cognitive and physical problems”. The questionnaire has been used in large 
published studies of HAND.2, 12, 13 
 
Symptoms of cognitive impairment were elicited using four questions from the Medical 
Outcomes Study in HIV (MOS-HIV)14 (see Supplemental Digital Content 2). Participants were 
asked to indicate how much of the time in the past four weeks they had experienced difficulty 
reasoning and solving problems, forgetfulness, trouble keeping their attention, and difficulty in 
concentration. Possible responses were scored: 0, none of the time; 1, a little bit of the time; 2, 
some of the time; 3, a good bit of the time; 4, most of the time; 5, all of the time. Adding the four 
responses gave a total score of 0-20. 
 
Participants completed the 9-item Patient Health Questionnaire (PHQ-9) for depression 15 and 
the 7-item Generalized Anxiety Disorder questionnaire (GAD-7) for anxiety.16 These 
questionnaires elicit symptom frequency in the past two weeks: 0, not at all; 1, several days; 2, 
more than half the days; 3, nearly every day. PHQ-9 scores ranged from 0-27 and were graded: 
0-4, none/minimal; 5-9, mild; 10-14, moderate; 15-19, moderate-severe; 20-27, severe. GAD-7 
scores ranged from 0-21 and were graded: 0-4, none/minimal; 5-9, mild; 10-14, moderate; 15-
21, severe.  
 
Cognitive testing  
The study used Cogstate, software adapted from standard NP tasks for assessment of multiple 
cognitive domains (http://cogstate.com/academic-2/measurement-of-cognition),17-19 and two 
pen-and-paper NP tests. Cogstate is mainly non-language-based and the stimuli vary randomly 
between assessments, reducing the influence of cultural, educational, and practice effects. 
Several studies have used Cogstate in HIV+ patients in Anglophone countries,20-26 with work 
demonstrating good construct validity and correlation with traditional pen-and-paper NP 
batteries,21-23 and the method has been used in children and adults in diverse settings in Africa 
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and Asia 27-29 (although not in all countries where CIPHER was based). Ten tests were organized 
into five domains: psychomotor speed (Detection and Identification); verbal memory (Shopping 
List learning and recall); executive function (Groton Maze learning and recall; these tests also 
assess visuospatial learning and memory); working memory (One-Back speed and accuracy); 
verbal fluency (two pen-and-paper tests: Controlled Oral Word Association Test [COWAT] and 
Category Fluency Test [CFT]). Testing included a full practice run (not scored) on the same day 
as the main assessment.30 
 
Each cognitive test was converted to an age-, sex-, and education-standardized Z-score using 
normative means and SD. Normative general population data for the computerized tests were 
provided by Cogstate from Europe, United States of America, South East Asia and Australia/New 
Zealand, frequency-matched for age (18-34, 35-50, and 51+ years; minimum cell size n=145), 
sex (157 female, 377 male), and education (university/further education, n=243, or secondary 
school, n=291). The normative population excluded individuals with clinical or functional 
impediments to test performance, and subsets of this data had been used previously to measure 
cognitive function in HIV+ adults.20-22, 24, 26 Published norms were used for the COWAT and 
CFT.31, 32 A continuous measure of neurocognitive function was calculated from the mean of all 
five domain Z scores (NPZ-5). 
 
Other data collection 
Drug and alcohol use, educational attainment and socioeconomic information were obtained 
from self-report. Medical and psychiatric history were obtained from both patient report and 
clinical notes. Clinical information included current HIV viral load (VL), CD4 count, ART history, 
HIV-related complications, laboratory markers, and neurological and psychiatric comorbidities. 
Hepatitis C (HCV) status was defined as the most recent HCV RNA assay, or the most recent 
antibody result in the absence of an RNA result. Participants with any of a pre-specified list of 
comorbid conditions (published as an appendix to the original criteria3) – including depressive 
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disorders, historical traumatic brain injury, developmental disabilities, alcohol and substance 
use disorders, certain HIV-related and non-HIV-related neurologic conditions, and systemic 
disease likely to affect cognition – were noted. We adopted the nomenclature used by the 
CHARTER group, where contributing conditions were those with potential for mild cognitive 
impairment, while confounding conditions were those likely to have a substantial effect on 
cognitive function.2  
 
Statistical analyses 
The first outcome measure was defined, using the IADLS, as self-reported decline in two or 
more ADLs out of the possible sixteen (designated “functionally dependent” by Obermeit et al 7) 
and attribution to cognitive problems by the participant. In order to harmonize our results with 
Obermeit and others, we included ADLs that had been omitted in our previous analysis,11 
namely planning social activities, reading / watching television, and childcare. The associations 
of age, sex, ethnic group (white versus other ethnic groups), study site, educational attainment 
(as ordered categories of primary, secondary and higher education), employment status (as a 
categorical variable of in employment, unable to work, or unemployed for other reasons), 
cognitive function (as a continuous variable by domain and as a mean score), clinical data and 
psychosocial variables were estimated by odds ratios (OR) and 95% confidence intervals (CI). 
All cognitive function scores and factors found to be at least moderately associated with the 
outcome (at a threshold of p<0.1) were included in separate logistic regression models with 
adjustment for demographic variables (age, sex, ethnic group, study site and education). 
Education, site and ethnicity have been identified as factors associated with cognitive test 
scores in an earlier analysis of the same study sample.11  
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The second outcome measure was symptom score from the MOS-HIV questionnaire in five 
ordered categories. The base category was defined as asymptomatic (0 points on the 
questionnaire) and subsequent categories corresponded to four quartiles of the remaining 
values. Ordered logistic regression was used to calculate ORs and CI for each factor in the same 
way as the ADL decline outcome measure. The ordered logistic model assumes the same effect 
size for each unit increase in the outcome. Multivariable regression models were also 
constructed for factors with p<0.1 in the bivariate analyses, adjusted for demographic variables, 
in the same way as the first outcome measure. 
 
Finally, we assessed the possible application of the IADLS and MOS-HIV symptom 
questionnaires as a diagnostic or screening tools for cognitive impairment. Two reference 
standards were employed, defined as low performance in two or more cognitive domains to a 
level of Z≤-1 (mild cognitive impairment) or Z≤-2 (severe cognitive impairment). Receiver 
operator curves (ROC) were generated from sensitivity and specificity statistics for all possible 
thresholds on each scale (number of ADLs of difficulty when attributed by the patient to 
cognitive problems, and MOS-HIV cognitive symptom score). Test accuracy statistics (positive 
and negative likelihood ratios [LR] and diagnostic odds ratios [DOR]) were calculated.  
 
RESULTS 
 
Study population 
Of 486 patients recruited, 448 (92%) completed all cognitive assessments (London, 292 [65%]; 
Rome 90 [20%]; Copenhagen 42 [9.4%]; Minsk 24 [5.4%]), 15 participants only completed the 
practice assessment and 23 completed fewer than five cognitive domains. The sample was 87% 
white, 84% male, mean 45.8 years of age (SD 9.6), 89% on ART and 81% with VL <50 
copies/mL. Participant characteristics are shown in Table 1 (breakdown by study site has 
already been published11). 
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Factors associated with self-reported decline in Activities of Daily Living 
Self-reported functional decline in two or more ADLs was present in 138 participants (30.8%). 
This was attributed to cognitive problems, with or without physical problems, by 96 (69.6% of 
those reporting decline). The most frequent difficulties were socializing, work and 
housekeeping, affecting 55-72% of functionally impaired patients and 5-15% of patients with 
fewer than two areas of difficulty (Figure 1). Information on specific ADLs was not available for 
participants at the Italian site (n=90), and 134 of the remainder (37.4%) left the childcare item 
blank or responded “I do not have children”; these individuals were assumed not to have 
declined in this activity.  
 
Several factors were associated with self-reported decline in ADLs attributed to cognitive 
impairment (Table 2). In models adjusted for age, sex, ethnic group, education and study site, a 
decline in ADLs was associated with speed / reaction time (aOR 0.68 per Z +1, 95% CI 0.55-
0.83) and attention / working memory (aOR 0.57 per Z +1, 95% CI 0.42-0.78). Other associated 
factors were: ability to afford basic needs most of the time (aOR 2.71, 95% CI 1.52-4.80) or 
some of the time (aOR 4.44, 95% CI 2.01-9.81) compared to those who were always able to 
afford basic needs; being unable to work (aOR 3.99, 95% CI 1.94-8.22) or unemployed for other 
reasons (aOR 2.21, 95% CI 1.26-3.86) compared to those in employment; depressive symptoms 
(aOR 2.06 per grade on the PHQ-9 scale, 95% CI 1.66-2.55); anxiety symptoms (aOR 2.20 per 
grade on the GAD-7 scale, 95% CI 1.69-2.88); and HIV diagnosis 5-10 years ago (aOR 3.18, 95% 
CI 1.42-7.13) or ≥10 years ago (aOR 3.62, 95% CI 1.62-8.09). 
 
To explore the interdependence of the effects of mood, cognition and functional abilities, we 
analyzed whether adjusting for relevant cognitive domains would change the association 
between PHQ-9 grade and self-reported decline in ADLs. The effect after including the speed 
domain was an adjusted odds ratio of 1.95 (95% CI 1.58-2.41), and the effect after including 
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attention and working memory was an aOR if 1.96 (95% CI 1.59-2.42), similar to the results of 
the simpler model. Additionally, there was no evidence of an interaction between depression 
and functional decline in their effects on the speed domain (p=0.37) or on the attention / 
working memory domain (p=0.84). 
 
Factors associated with self-reported symptoms of cognitive impairment 
MOS-HIV scores were available for 440 participants, with a median score of 4 (IQR 1-8). 
Numbers in each of the five ordered categories were: 86 asymptomatic (0 points, 19.6%); 115 
with grade 1 (1-3 points, 26.1%); 70 with grade 2 (4-5 points, 15.9%); 85 with grade 3 (6-9 
points, 19.3%); 84 with grade 4 (10-20 points, 19.1%). In multivariable ordered logistic 
regression models adjusted for age, sex, ethnic group, education and study site, increasing grade 
of symptom frequency was associated with impairment of speed / reaction time (aOR 0.68 per 
+1 in Z score, 95% CI 0.58-0.80), attention / working memory (aOR 0.60, 95% CI 0.47-0.77), 
verbal memory (aOR 0.87, 95% CI 0.77-0.98) and verbal fluency (aOR 0.84, 95% CI 0.71-1.00). 
Other associated factors were: being educated to only primary school level, compared to 
completing higher education (aOR 1.89, 95% CI 1.17-3.05); confounding (aOR 2.07, 95% CI 
1.31-3.27) or contributing medical conditions (aOR 2.02, 95% CI 1.22-3.36); ability to afford 
basic needs most of the time (aOR 1.91, 95% CI 1.25-2.90), some of the time (aOR 3.56, 95% CI 
1.86-6.82) or not at all (aOR 3.80, 95% CI 1.85-7.81); being unable to work (aOR 4.68, 95% CI 
2.55-8.59) or unemployed for other reasons (aOR 2.11, 95% CI 1.41-3.14) compared to those in 
employment; depressive symptoms (aOR 2.75 per grade on the PHQ-9, 95% CI 2.28-3.32); 
anxiety symptoms (aOR 3.24 per grade on the GAD-7, 95% CI 2.58-4.07); and ≥10 years since 
HIV diagnosis (aOR 1.82, 95% CI 1.12-2.97).  
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Accuracy of the questionnaires as tests for cognitive impairment 
After excluding participants with incomplete data, the IADLS had sensitivity 40%, specificity 
78% when used as a test for severe cognitive impairment (prevalence 30/356, 8.4%) with a cut-
off of decline in ≥ 2 ADLs (Figure 3). There were 12 true positives, 253 true negatives, 73 false 
positives and 18 false negatives, equating to positive LR 1.79, negative LR 0.77 and DOR 2.31. 
The questionnaire had worse sensitivity and better specificity when used with a cut-off of a 
higher number of ADLs, and LRs and DORs were consistently poor (close to 1).  
 
The most balanced trade-off between sensitivity and specificity on the MOS-HIV symptom scale 
was at a cut-off of ≥7 points, giving sensitivity 48%, specificity 69% as a test for severe cognitive 
impairment (prevalence 48/440, 10.9%). There were 23 true positives, 271 true negatives, 121 
false positives and 25 false negatives, giving positive LR 1.55, negative LR 0.75 and DOR 2.06. 
The questionnaire had better accuracy overall at higher cut-offs at the expense of poor 
sensitivity (high false negative rates). At lower cut-offs in the range of 2-5 points, sensitivity was 
improved at 50-73% but specificity was markedly down at 27-57% and both positive LR and 
DOR were consistently <2.  
 
Both questionnaires were, in general, less sensitive and less specific when compared to a 
reference standard of mild cognitive impairment. We conducted exploratory analyses with 
exclusion of the most severely anxious or depressed participants, and this made no 
improvement to the diagnostic accuracy statistics for either outcome measure (IADLS or MOS-
HIV score). 
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DISCUSSION 
 
In this study of HIV+ outpatients at five clinics in Europe, 80% reported cognitive symptoms in 
the past four weeks, and just over 20% reported decline in their ADLs and attributed this to 
cognitive impairment. There were associations between poorer cognitive function (especially 
reaction time, speed and attention) and both self-reported decline in ADLs and increasing 
frequency of cognitive symptoms. However, symptoms of depression and anxiety, longer time 
since HIV diagnosis, unemployment, and difficulty affording basic needs were also strongly 
associated with cognition-related symptoms and functional decline. Additionally, lower 
educational attainment and comorbid medical conditions were associated with cognitive 
symptoms. All of our observed associations may have multiple explanations, and causality could 
be in either direction (particularly in the relationships between employment and financial 
means and the outcomes of interest). The accuracy of both questionnaires, modelled as 
diagnostic tests for cognitive impairment, was relatively poor and below a level likely to be 
acceptable for individual patient use.  
 
These results imply that patients who report symptoms of cognitive impairment, or declining 
everyday function, should be assessed for depression, anxiety, concomitant medical conditions 
and financial difficulties. Failure to recognize these important elements of patients’ lived 
experiences risks diagnostic delay, failure to address important needs, unnecessary 
investigations and further anxiety. This is similar to the conclusions of a large cohort study of 
HIV-negative older adults in Amsterdam: “when an older person complains about his or her 
memory and does not show actual cognitive impairment or cognitive decline, one should be 
aware that these complaints might reflect psycho-affective or health problems. Adequate 
intervention in these psycho-affective or health problems may improve quality of life”.33 
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The relationships between cognitive impairment, low mood, and functional decline are complex 
and multidirectional. Secondary analyses suggested the effects of mood and cognition on 
everyday function were relatively independent, although we cannot exclude other explanations. 
In our recently-published report of the same study population, we showed that severe 
depressive symptoms were associated with cognitive impairment, particularly on timed tests.11 
A controlled intervention to improve patients’ depression or anxiety symptoms might tease out 
the effect of low of mood on subjective and objective cognitive outcomes. 
 
Limitations to CIPHER study methodology and Cogstate in general have been discussed in 
earlier reports 11, 25 but some deserve further mention here. Notably, selection biases may have 
arisen as a result of our opportunistic sampling strategy, with patients choosing to participate in 
the study on the basis of their own concerns and self-perceived cognitive symptoms. Also, the 
largely computerized neuropsychological methods did not provide as comprehensive an 
assessment as traditional assessment conducted by a neuropsychologist. Importantly, the lack 
of HIV-negative controls prevents us from determining whether our findings are specific to 
PLWH. However, there is a body of literature from the general population concluding that 
psychological and psychiatric factors are as important as cognitive function to subjective 
memory complaints. In their conceptual framework for research into subjective cognitive 
decline (SCD) in pre-clinical Alzheimer’s disease, Jessen et al note that mood- and anxiety-
related symptoms may be both a confounder of the relationship between SCD and subsequent 
dementia and an early symptom of dementia.34 An analogous situation might be at work in HIV-
related cognitive impairment. 
 
Despite initially positive results with a three-question symptom tool 1 and the MOS-HIV 
cognitive questions,35 several studies have reported poor test accuracy of ADL and cognitive 
symptom scales in HIV+ patients.7-10 In 290 PLWH over 50 years in Great Britain and Ireland 
and 97 seronegative controls, other patient-reported outcome measures, including depression, 
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falls, sexual function and general health, correlated poorly with cognitive impairment.8 Thames 
et al divided 107 HIV positive patients into 4 groups, on the basis of whether they were 
impaired or unimpaired, and whether they were accurate or inaccurate in their self-assessment 
of this. Notably, only 38% were accurate, 33% were impaired but did not report a decline, and 
25% reported a decline but did not have cognitive impairment.36 In similar studies, it was 
reported that only 33% 37 and 37% 38 of patients gave answers to symptom questions that 
concurred with their objective cognitive test scores. In an analysis of CNS HIV Anti-Retroviral 
Therapy Effects Research (CHARTER) cohort patients (n=277) in the United States, impaired 
everyday function was associated with depression, unemployment, findings on neuromedical 
examination and physician-assigned Karnofsky score. While patients were able to rate their 
own overall level of ability they were poor at correctly attributing their difficulties to cognitive 
versus physical problems.7 
 
Patients’ symptoms are important because they guide clinical decisions, but clearly there are 
reasons other than neurological disease why patients and study participants may report 
symptoms. First, PLWH may have psychiatric problems, excessive substance use, or some other 
reversible cause for their symptoms. Second, depression or anxiety may cause them to perceive 
a functional decline that is not present. Third, they may be hypervigilant for symptoms or 
worried about normal everyday experiences, although not suffering from any psychiatric 
disorder. Fourth, there may be desirability bias: they say what they think the clinician or 
researcher wants to hear. Fifth, there may be secondary gain as a result of misreporting their 
symptoms. And sixth, the measuring instruments may lack construct validity and fail to measure 
what they purport to measure. 
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Differentiation of asymptomatic from symptomatic HAND relies solely on estimating daily 
function at ADL, and most published research in this area relies predominantly on participants’ 
self-report. There are limited data on more accurate and reliable measures of everyday 
performance, such as third-party observation or performance-based measures.12, 13 This has 
crucial implications for the interpretation of longitudinal studies in which the risk of change 
from ANI to MND is measured, such as the United States CHARTER cohort,39 the Canadian OHTN 
Cohort,6 and the French Aquitaine cohort.40 For example, in the Ottawa cohort, depression was a 
major risk factor for change from ANI to MND.6 Since self-reported functional impairment is 
associated with depression, change from ANI to MND does not always indicate decline in 
neurocognitive abilities. Nor should change from ANI to MND in longitudinal studies be viewed 
as progressive, unidirectional deterioration (as is implied by the use of Kaplan-Meier plot 
analyses). The CHARTER cohort used a more robust method of both self-reported and 
performance-based assessments to discriminate ANI from MND.39 These issues should be taken 
into consideration in the design and analysis of future HAND cohort studies.  
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FIGURE LEGENDS 
 
Figure 1. Proportion of patients reporting decline in specific activities of daily living who were 
functionally impaired (n=117) or not functionally impaired (n=241). 
 
Figure 2. Receiver-operator curves showing sensitivity and specificity of (left) number of Activities of 
Daily Living affected and (right) symptom frequency score as tests for mild (dashed line) or severe 
(solid line) cognitive impairment. The dotted diagonal line shows the line of no diagnostic 
information. 
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Table 1. Characteristics of HIV Positive Study Participants (N=448). 
 n/N % Mean (SD) or median 
(IQR) 
Age, years   45.8 (9.6) 
Male sex 378/448 84.4  
MSM 306/429 71.3  
White ethnicity 389/440 88.4  
Migrant * 118/429 27.5  
Can always afford basic needs 247/429 57.6  
Educational attainment: 
University or other higher education 
Secondary school 
Primary school 
 
249/429 
101/429 
79/429 
 
58.0 
23.5 
18.4 
 
Employment status: 
In employment 
Unable to work 
Other reasons for unemployment 
 
255/421 
43/421 
123/421 
 
60.6 
10.2 
29.2 
 
Recent psychoactive drug use † 132/448 29.5  
Any previous IDU 40/448 8.9  
Problem drinking ‡  167/428 39.0  
Major depressive symptoms § 111/436 25.5  
Major anxiety symptoms § 87/435 20.0  
Latest CD4 count, cells/μL    550 (410, 750) 
Nadir CD4 count, cells/μL   290 (160, 500) 
Years since positive HIV result   9.9 (4.8, 16.2) 
On ART 400/448 89.3  
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HIV RNA <50 copies/mL 363/448 81.0  
HCV ǁ 64/441 14.5  
* Defined as those not born in the country of assessment. 
† Defined as self-reported consumption of amphetamines (including methamphetamine), 
cocaine, cannabis, opiates for non-medicinal use, ketamine, gamma-hydroxybutyrate, 
gamma-butyrolactone, psychedelics or mephedrone in the past 3 months. 
‡ Defined by the modified (two-question) AUDIT-C questionnaire: a positive score was ≥4 
points for men or ≥3 points for women. 
§ Defined as ≥10 points on the PHQ-9 (depression) or GAD-7 (anxiety) scale. 
ǁ Defined as the most recent HCV RNA assay, or the most recent antibody result in the 
absence an RNA result. 
ART, anti-retroviral therapy; HCV, hepatitis C virus; IDU, intravenous drug use; IQR, inter-
quartile range; MSM, men who have sex with men; SD, standard deviation. 
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 Table 2. Factors Associated with Self-Reported Decline in ADL Attributed to Cognitive Impairment. 
 Unadjusted OR 
(95% CI) 
P Adjusted OR  
(95% CI) * 
P 
Age per +10 years 1.09 (0.86-1.38) 0.49 0.96 (0.73-1.26) 0.78 
Gender and sexual 
orientation 
    
MSM 
Other men 
Women 
1 
1.25 (0.70-2.26) 
0.52 (0.24-1.09) 
 
 
0.13 
1 
1.66 (0.75-3.71) 
0.93 (0.40-2.16) 
 
 
0.39 
Ethnic group     
White 
Other or not known 
1 
2.11 (1.17-3.83) 
 
0.014 
1 
1.21 (0.59-2.48) 
 
0.60 
Education ‡     
University / higher 
Secondary  
Primary only 
1 
0.80 (0.44-1.47) 
1.53 (0.85-2.73) 
 
 
0.27 
1 
0.92 (0.48-1.78) 
1.41 (0.76-2.62) 
 
 
0.35 
Employment status     
In employment 
Unable to work 
Other 
1 
5.47 (2.72-10.98) 
2.36 (1.43-3.92) 
 
 
<0.0001 
1 
3.99 (1.94-8.22) 
2.21 (1.26-3.86) 
 
 
0.0003 
Site     
London 
Rome 
Copenhagen 
Minsk 
1 
0.36 (0.18-0.72) 
0.20 (0.06-0.67) 
0.11 (0.02-0.85) 
 
 
 
0.0004 
1 
0.33 (0.15-0.71) 
0.23 (0.07-0.76) 
0.11 (0.01-0.92) 
 
 
 
0.002 
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Mean Z (all domains) per 
+1 SD 
0.76 (0.61-0.96) 0.019 0.70 (0.54-0.91) 0.009 
Speed Z per +1 SD 0.75 (0.63-0.90) 0.002 0.68 (0.55-0.83) <0.0005 
Attention / working 
memory Z per +1 SD 
0.68 (0.51-0.90) 0.006 0.57 (0.42-0.78) <0.0005 
Executive function Z per 
+1 SD 
0.96 (0.88-1.05) 0.41 0.97 (0.88-1.07) 0.56 
Verbal memory Z per +1 
SD 
0.92 (0.81-1.06) 0.26 0.90 (0.77-1.06) 0.22 
Verbal fluency Z per +1 
SD 
0.87 (0.70-1.08) 0.21 0.87 (0.69-1.10) 0.24 
Confounding co-morbid 
condition † 
    
No 
Yes 
1 
1.86 (1.09-0.51) 
 
0.024 
1 
1.61 (0.91-2.84) 
 
0.10 
Contributing co-morbid 
condition † 
    
No 
Yes 
1 
1.57 (0.86-2.87) 
 
0.14 
  
Can afford basic needs ‡     
Always 
Most of the time 
Some of the time 
No 
1 
2.64 (1.53-4.56) 
4.05 (1.93-8.51) 
2.47 (1.01-6.03) 
 
 
 
0.0002 
1 
2.71 (1.52-4.80) 
4.44 (2.01-9.81) 
2.40 (0.94-6.11) 
 
 
 
0.0003 
Recreational psychoactive 
drugs in past 3 months 
    
No 1    
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Yes 1.42 (0.88-2.29) 0.15 
Problem drinking §     
No 
Yes 
1 
1.41 (0.88-2.25) 
 
0.15 
  
Depressive symptoms per 
grade ‡ ǁ 
2.11 (1.73-2.57) <0.0005 2.06 (1.66-2.55) <0.0005 
Anxiety symptoms per 
grade ‡ ǁ 
1.98 (1.57-2.50) <0.0005 2.20 (1.69-2.88) <0.0005 
Hepatitis C status ‡ ¶     
Negative 
Positive 
1 
1.63 (0.89-2.97) 
 
0.11 
  
ART and VL status     
VL <50 on ART 
Detectable on ART 
Off ART 
1 
1.81 (0.87-3.77) 
0.76 (0.34-1.68) 
 
 
0.19 
  
Current CD4 count per 
+100 cells/mm3 
 
0.99 (0.91-1.09) 
 
0.88 
  
Nadir CD4 count per +100 
cells/mm3 
 
1.00 (0.91-1.09) 
 
0.94 
  
Time since HIV diagnosis     
<5 years  
5-10 years 
≥10 years 
1 
4.09 (1.90-8.77) 
3.36 (1.64-6.90) 
 
 
0.001 
1 
3.18 (1.42-7.13) 
3.62 (1.62-8.09) 
 
 
0.005 
Previous AIDS     
No 
Non-CNS 
CNS conditions 
1 
0.93 (0.49-1.77) 
1.57 (0.40-6.22) 
 
 
0.79 
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* Adjusted models include age, sex, education, ethnic group and study site. 
† Confounding and contributing medical conditions as defined by the Frascati criteria 3 and 
CHARTER cohort analysis.2 
‡ Excludes missing data.  
§ Defined by the modified (two-question) AUDIT-C questionnaire: a positive score was ≥4 
points for men or ≥3 points for women. 
ǁ Depression (PHQ-9) grades were: 0-4, none/minimal; 5-9, mild; 10-14, moderate; 15-19, 
moderate-severe; 20-27, severe. Anxiety (GAD-7) grades were: 0-4, none/minimal; 5-9, mild; 
10-14, moderate; 15-21, severe. 
¶ Defined as the most recent HCV RNA assay, or the most recent antibody result in the 
absence an RNA result. 
ART, antiretroviral therapy; CI, confidence interval; CNS, central nervous system; GAD-7, 
generalised anxiety disorder 7-item scale; MSM, men who have sex with men; OR, odds ratio; 
PHQ-9, patient health questionnaire 9-item scale; SD, standard deviation. 
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 Table 3. Factors Associated with Frequency of Symptoms of Neurocognitive Impairment. 
 Crude OR (95% 
CI) 
P Adjusted OR 
(95% CI) * 
P 
Age per +10 years 0.96 (0.81-1.13) 0.59 0.93 (0.77-1.12) 0.43 
Gender and sexual 
orientation 
    
MSM 
Other men 
Women 
1 
1.14 (0.72-1.81) 
1.12 (0.70-1.79) 
 
 
0.79 
1 
1.23 (0.69-2.19) 
1.75 (0.98-3.12) 
 
 
0.16 
Ethnic group     
White 
Other or not known 
1 
1.67 (1.00-2.77) 
 
0.048 
1 
1.15 (0.65-2.02) 
 
0.64 
Education     
University / higher 
Secondary  
Primary only 
1 
1.22 (0.81-1.84) 
1.77 (1.12-2.80) 
 
 
0.016 
1 
1.25 (0.80-1.95) 
1.89 (1.17-3.05) 
 
 
0.010 
Employment status     
In employment 
Unable to work 
Other 
1 
5.60 (3.12-10.1) 
2.12 (1.47-3.08) 
 
 
<0.0001 
1 
4.68 (2.55-8.59) 
2.11 (1.41-3.14) 
 
 
<0.0001 
Site     
London 
Rome 
Copenhagen 
Minsk 
1 
0.47 (0.30-0.72) 
0.36 (0.20-0.65) 
0.54 (0.26-1.15) 
 
 
 
0.0001 
1 
0.38 (0.23-0.62) 
0.41 (0.23-0.76) 
0.44 (0.18-1.10) 
 
 
 
0.0002 
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Mean Z (all domains) per 
+1 SD 
0.78 (0.65-0.92) 0.005 0.71 (0.58-0.87) 0.001 
Speed Z per +1 SD 0.71 (0.62-0.82) <0.0005 0.68 (0.58-0.80) <0.0005 
Attention / working 
memory Z per +1 SD 
0.67 (0.54-0.84) <0.0005 0.60 (0.47-0.77) <0.0005 
Executive function Z per +1 
SD 
0.99 (0.92-1.06) 0.73 0.99 (0.92-1.07) 0.86 
Verbal memory Z per +1 SD 0.93 (0.84-1.03) 0.17 0.87 (0.77-0.98) 0.025 
Verbal fluency Z per +1 SD 0.85 (0.72-1.00) 0.043 0.84 (0.71-1.00) 0.044 
Confounding co-morbid 
condition †  
    
No 
Yes 
1 
2.30 (1.47-3.61) 
 
<0.0005 
1 
2.07 (1.31-3.27) 
 
0.002 
Contributing co-morbid 
condition † 
    
No 
Yes 
1 
1.80 (1.12-2.89) 
 
0.016 
1 
2.02 (1.22-3.36) 
 
0.006 
Can afford basic needs ‡     
Always 
Most of the time 
Some of the time 
No 
1 
1.98 (1.31-2.97) 
3.69 (1.95-6.96) 
4.25 (2.09-8.66) 
 
 
 
<0.0001 
1 
1.91 (1.25-2.90) 
3.56 (1.86-6.82) 
3.80 (1.85-7.81) 
 
 
 
<0.0001 
Recreational psychoactive 
drugs in past 3 months 
    
No 
Yes 
1 
1.43 (0.99-2.05) 
 
0.054 
1 
1.16 (0.79-1.72) 
 
0.47 
Problem drinking ‡ §     
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No 
Yes 
1 
1.16 (0.82-1.64) 
 
0.69 
  
Depressive symptoms per 
grade ‡ ǁ 
2.92 (2.43-3.50) <0.0005 2.75 (2.28-3.32) <0.0005 
Anxiety symptoms per 
grade ‡ ǁ 
 
3.28 (2.63-4.07) 
 
<0.0005 
 
3.24 (2.58-4.07) 
 
<0.0005 
Hepatitis C status ‡ ¶     
Negative 
Positive 
1 
1.18 (0.75-1.87) 
 
0.47 
  
ART and VL status     
VL <50 on ART 
Detectable on ART 
Off ART 
1 
1.37 (0.71-2.64) 
0.93 (0.54-1.59) 
 
 
0.61 
  
Current CD4 count per 
+100 cells 
 
0.97 (0.91-1.04) 
 
0.36 
  
Nadir CD4 count per +100 
cells 
 
0.99 (0.93-1.06) 
 
0.83 
  
Time since HIV diagnosis     
<5 years 
5-10 years 
≥10 years 
1 
1.45 (0.91-2.30) 
1.62 (1.08-2.43) 
 
 
0.024 
1 
1.26 (0.77-2.06) 
1.82 (1.12-2.97) 
 
 
0.014 
Previous AIDS     
None 
Non-CNS 
CNS condition 
1 
1.36 (0.86-2.16) 
2.28 (0.73-7.10) 
 
 
0.17 
  
* Adjusted models include age, sex, education, ethnic group and study site. 
† Confounding and contributing medical conditions as defined by the Frascati criteria 3 and 
CC
EP
TE
D
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. 
CHARTER cohort analysis.2 
‡ Excludes missing data.  
§ Defined by the modified (two-question) AUDIT-C questionnaire: a positive score was ≥4 
points for men or ≥3 points for women. 
ǁ Depression (PHQ-9) grades were: 0-4, none/minimal; 5-9, mild; 10-14, moderate; 15-19, 
moderate-severe; 20-27, severe. Anxiety (GAD-7) grades were: 0-4, none/minimal; 5-9, mild; 
10-14, moderate; 15-21, severe. 
¶ Defined as the most recent HCV RNA assay, or the most recent antibody result in the 
absence an RNA result. 
ART, antiretroviral therapy; CI, confidence interval; CNS, central nervous system; GAD-7, 
generalised anxiety disorder 7-item scale; MSM, men who have sex with men; OR, odds ratio; 
PHQ-9, patient health questionnaire 9-item scale; SD, standard deviation. 
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